CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.14), FiscalAI reports.
CNS Pharmaceuticals Stock Performance
Shares of CNSP traded up $0.20 during trading hours on Thursday, reaching $5.21. The stock had a trading volume of 728 shares, compared to its average volume of 596,769. CNS Pharmaceuticals has a 12 month low of $1.90 and a 12 month high of $10.59. The stock has a market capitalization of $7.60 million, a PE ratio of -0.18 and a beta of 3.05. The company’s 50-day moving average is $4.95 and its two-hundred day moving average is $4.18.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $20.00.
Insider Buying and Selling at CNS Pharmaceuticals
In other news, Director Faith L. Charles acquired 7,100 shares of CNS Pharmaceuticals stock in a transaction that occurred on Monday, May 18th. The shares were acquired at an average price of $4.79 per share, for a total transaction of $34,009.00. Following the transaction, the director directly owned 7,100 shares of the company’s stock, valued at approximately $34,009. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.01% of the stock is currently owned by company insiders.
Institutional Trading of CNS Pharmaceuticals
A number of hedge funds have recently made changes to their positions in the company. Armistice Capital LLC bought a new stake in shares of CNS Pharmaceuticals during the second quarter worth about $335,000. Ikarian Capital LLC bought a new position in CNS Pharmaceuticals in the 4th quarter valued at approximately $241,000. Finally, Boothbay Fund Management LLC bought a new position in CNS Pharmaceuticals in the 4th quarter valued at approximately $71,000. 14.02% of the stock is owned by institutional investors and hedge funds.
About CNS Pharmaceuticals
CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.
Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.
Featured Stories
- Five stocks we like better than CNS Pharmaceuticals
- SpaceX’s First Earnings Report Only Made Wall Street More Divided
- Plug Power Charges Ahead: Margin Expansion Sparks a Rally
- Abercrombie’s Comeback Is a Work in Progress
- Roku’s Ad Business Is Growing—These 3 Stocks Could Be Next
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
